Akèy › Kansè nan tete › Texas › Fort Worth
Etid klinik pou Kansè nan tete nan Fort Worth, TX
11 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Fort Worth (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
IKS014 in Advanced Solid Tumors That Express HER2
Ap rekriteFaz 1
- START Dallas - Fort Worth, Fort Worth
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Ap rekriteFaz 3
- JPS Health Network ( Site 0067), Fort Worth
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- JPS Oncology and Infusion Center ( Site 0083), Fort Worth
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- The Center for Cancer and Blood Disorders ( Site 0041), Fort Worth
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Ap rekriteFaz 3
- JPS Health Network, Fort Worth
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- JPS Health Network - Trinity Springs Pavilion, Fort Worth
- OneR The Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth
- UT Southwestern Moncrief Cancer Institute, Fort Worth
- ak 2 plis
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Start - Dfw, Fort Worth
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Fort Worth
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- JPS Health Network, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Texas Oncology, Fort Worth
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Fort Worth
- Kansè Poumon ki pa ti selil18 etid
- Kansè ovè17 etid
- Kansè Endomèt12 etid
- Kansè (tout kalite)9 etid
- Kansè pwostat9 etid
- Ensifizyans kadyak7 etid
- Kansè kolorektal7 etid
- Kansè tete negatif triple7 etid
- Kansè Metastatik7 etid
- Kansè renn (Kasinom selil renn)7 etid
- Kolit Ulseratif7 etid
- Degeneresans makile7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.